Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value

In This Article:

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 closing lower due to weak trade data from China and declining commodity prices affecting major companies. In this environment of uncertainty, investors may be on the lookout for stocks that are undervalued relative to their intrinsic value, as these can present potential opportunities despite broader market fluctuations.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

Name

Current Price

Fair Value (Est)

Discount (Est)

Begbies Traynor Group (AIM:BEG)

£0.916

£1.68

45.6%

Savills (LSE:SVS)

£9.27

£16.53

43.9%

Gooch & Housego (AIM:GHH)

£3.77

£7.13

47.1%

Aptitude Software Group (LSE:APTD)

£2.79

£5.13

45.7%

GlobalData (AIM:DATA)

£1.775

£3.32

46.6%

On the Beach Group (LSE:OTB)

£2.65

£4.78

44.5%

Entain (LSE:ENT)

£6.376

£12.03

47%

ECO Animal Health Group (AIM:EAH)

£0.695

£1.28

45.6%

Kromek Group (AIM:KMK)

£0.051

£0.10

49.7%

Ibstock (LSE:IBST)

£1.80

£3.24

44.5%

Click here to see the full list of 52 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

GlobalData

Overview: GlobalData Plc, along with its subsidiaries, offers business information through proprietary data, analytics, and insights across Europe, North America, and the Asia Pacific with a market cap of £1.35 billion.

Operations: The company's revenue is derived from its Data, Analytics and Insights segments, with £109.40 million from Healthcare and £176.10 million from Non-Healthcare sectors.

Estimated Discount To Fair Value: 46.6%

GlobalData is trading at £1.78, significantly below its estimated fair value of £3.32, indicating it may be undervalued based on cash flows. Despite a volatile share price and a reduced dividend, the company is forecast to grow earnings by 21% annually, outpacing the UK market's growth rate. Recent M&A interest from ICG and KKR highlights potential strategic value, while an active share buyback program aims to enhance shareholder returns amidst plans to move to the Main Market.

AIM:DATA Discounted Cash Flow as at May 2025
AIM:DATA Discounted Cash Flow as at May 2025

AstraZeneca

Overview: AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines, with a market cap of approximately £166.35 billion.

Operations: The company's revenue primarily stems from its biopharmaceuticals segment, which generated $54.98 billion.

Estimated Discount To Fair Value: 42.9%